{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:38:25Z","timestamp":1790289505797,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"The National Institute of Cancer"},{"name":"La Fondation ARC pour la recherche sur le cancer et la Ligue contre le cancer. This work was supported by CANCER-ID"},{"name":"Innovative Medicines Initiative Joint Undertaking","award":["115749"],"award-info":[{"award-number":["115749"]}]},{"name":"European Union\u2019s Seventh Framework Program","award":["FP7\/2007-2013"],"award-info":[{"award-number":["FP7\/2007-2013"]}]},{"name":"EFPIA companies\u2019 in-kind contribution, by the SIRIC Montpellier Cancer","award":["INCa_Inserm_DGOS_12553"],"award-info":[{"award-number":["INCa_Inserm_DGOS_12553"]}]},{"name":"European Union Horizon 2020 Research and Innovation program under the Marie Sk\u0142odowska-Curie","award":["765492"],"award-info":[{"award-number":["765492"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the tumor biopsy spatiotemporal heterogeneity. However, the prognostic significance of PD-L1-positive [PD-L1(+)] CTCs remains controversial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We prospectively evaluated the correlation with clinicopathological variables and prognostic value of PD-L1(+) CTCs, detected with the FDA-cleared CellSearch\u00ae system, in 54 patients with advanced NSCLC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We detected CTCs and PD-L1(+) CTCs in 43.4% and 9.4% of patients with NSCLC. PD-L1 expression concordance between tumor tissue and CTCs was low (54%). The presence of PD-L1(+) CTC correlated with the absence of gene alterations in tumor tissue and with poor prognosis-related biological variables (anemia, hyponatremia, increased lactate dehydrogenase). In univariate analysis, absence of gene alterations, number of metastatic sites, prior systemic therapies, and presence of CTCs and PD-L1(+) CTCs were associated with worse overall survival, whereas PD-L1 expression in tumor tissue was not. In multivariate analysis, squamous cell carcinoma histology, number of prior systemic treatments, and the presence of CTC were significantly associated with overall survival. Survival was worse in patients with PD-L1(+) CTCs than in patients with PD-L1-negative CTC or without any CTC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study suggests that the presence of PD-L1(+) CTCs is associated with poor prognosis in patients with advanced NSCLC. Studies with larger samples are needed to confirm our results and to determine how PD-L1(+) CTC detection could help to predict the response or resistance to anti-PD-1\/PD-L1 therapies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>\u2002<\/jats:title>\n                  <jats:p>Clinical trial registration NCT02866149<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/clinchem\/hvab131","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T19:18:00Z","timestamp":1624907880000},"page":"1503-1512","source":"Crossref","is-referenced-by-count":70,"title":["Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer"],"prefix":"10.1093","volume":"67","author":[{"given":"L\u00e9a","family":"Sinoquet","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Institut du Cancer Montpellier, Montpellier University, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Jacot","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut du Cancer Montpellier, Montpellier University, Montpellier, France"},{"name":"Institut de Recherche en Canc\u00e9rologie de Montpellier, INSERM U1194, Montpellier University, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Gauthier","sequence":"additional","affiliation":[{"name":"Biometrics Unit, Institut du Cancer Montpellier, Montpellier University, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Pouderoux","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut du Cancer Montpellier, Montpellier University, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Viala","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut du Cancer Montpellier, Montpellier University, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Cayrefourcq","sequence":"additional","affiliation":[{"name":"Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, Montpellier, France"},{"name":"CREEC\/CANECEV, MIVEGEC (CREES), University of Montpellier, CNRS, IRD, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Quantin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut du Cancer Montpellier, Montpellier University, Montpellier, France"},{"name":"Institut de Recherche en Canc\u00e9rologie de Montpellier, INSERM U1194, Montpellier University, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Alix-Panabi\u00e8res","sequence":"additional","affiliation":[{"name":"Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, Montpellier, France"},{"name":"CREEC\/CANECEV, MIVEGEC (CREES), University of Montpellier, CNRS, IRD, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"key":"2021110213250350400_hvab131-B1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2021110213250350400_hvab131-B2","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"2021110213250350400_hvab131-B3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"2021110213250350400_hvab131-B4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2021110213250350400_hvab131-B5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"2021110213250350400_hvab131-B6","doi-asserted-by":"crossref","first-page":"a037333","DOI":"10.1101\/cshperspect.a037333","article-title":"The different facets of liquid biopsy: a kaleidoscopic view","volume":"10","author":"Eslami-S","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2021110213250350400_hvab131-B7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease \u2014 latest advances and implications for cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2021110213250350400_hvab131-B8","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3390\/cancers11070920","article-title":"Is the blood an alternative for programmed cell death ligand 1 assessment in non-small cell lung cancer?","volume":"11","author":"Acheampong","year":"2019","journal-title":"Cancers"},{"key":"2021110213250350400_hvab131-B9","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","article-title":"Liquid biopsy: from discovery to clinical application","volume":"11","author":"Alix-Panabi\u00e8res","year":"2021","journal-title":"Cancer Discov"},{"key":"2021110213250350400_hvab131-B10","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/annonc\/mdz196","article-title":"Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?","volume":"30","author":"Hofman","year":"2019","journal-title":"Ann Oncol"},{"key":"2021110213250350400_hvab131-B11","doi-asserted-by":"crossref","first-page":"31726","DOI":"10.1038\/srep31726","article-title":"Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor nivolumab","volume":"6","author":"Nicolazzo","year":"2016","journal-title":"Sci Rep"},{"key":"2021110213250350400_hvab131-B12","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3390\/cancers12061556","article-title":"Optimization of the enrichment of circulating tumor cells for downstream phenotypic analysis in patients with non-small cell lung cancer treated with anti-PD-1 immunotherapy","volume":"12","author":"Papadaki","year":"2020","journal-title":"Cancers"},{"key":"2021110213250350400_hvab131-B13","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1158\/1055-9965.EPI-17-0120","article-title":"Cellular expression of PD-L1 in the peripheral blood of lung cancer patients is associated with worse survival","volume":"26","author":"Boffa","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021110213250350400_hvab131-B14","first-page":"9","article-title":"PD-L1 expression in circulating tumor cells increases during radio(chemo)therapy and indicates poor prognosis in non-small cell lung cancer","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"key":"2021110213250350400_hvab131-B15","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/clinchem\/hvaa121","article-title":"Clinical correlations of programmed cell death ligand 1 status in liquid and standard biopsies in breast cancer","volume":"66","author":"Jacot","year":"2020","journal-title":"Clin Chem"},{"key":"2021110213250350400_hvab131-B16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/cancers6010153","article-title":"Evaluation of circulating tumor cells and related events as prognostic factors and surrogate biomarkers in advanced NSCLC patients receiving first-line systemic treatment","volume":"6","author":"Muinelo-Romay","year":"2014","journal-title":"Cancers"},{"key":"2021110213250350400_hvab131-B17","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdx156","article-title":"A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups","volume":"28","author":"Lindsay","year":"2017","journal-title":"Ann Oncol"},{"key":"2021110213250350400_hvab131-B18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2019.04.019","article-title":"EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer","volume":"117","author":"Lindsay","year":"2019","journal-title":"Eur J Cancer"},{"key":"2021110213250350400_hvab131-B19","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.2010.28.7045","article-title":"Evaluation and prognostic significance of circulating tumor cells in patients with non\u2013small-cell lung cancer","volume":"29","author":"Krebs","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021110213250350400_hvab131-B20","doi-asserted-by":"crossref","first-page":"5727815","DOI":"10.1155\/2017\/5727815","article-title":"Circulating tumor cells were associated with the number of T lymphocyte subsets and NK cells in peripheral blood in advanced non-small-cell lung cancer","volume":"2017","author":"Ye","year":"2017","journal-title":"Dis Markers"},{"key":"2021110213250350400_hvab131-B21","first-page":"2233","article-title":"Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer","volume":"33","author":"Gruber","year":"2013","journal-title":"Anticancer Res"},{"key":"2021110213250350400_hvab131-B22","doi-asserted-by":"crossref","first-page":"100953","DOI":"10.1016\/j.tranon.2020.100953","article-title":"Cell by cell immuno- and cancer marker profiling of non-small cell lung cancer tissue: checkpoint marker expression on CD103+, CD4+ T-cells predicts circulating tumor cells","volume":"14","author":"Wang","year":"2021","journal-title":"Transl Oncol"},{"key":"2021110213250350400_hvab131-B23","doi-asserted-by":"crossref","first-page":"pky028","DOI":"10.1093\/jncics\/pky028","article-title":"Association of metabolic, inflammatory, and tumor markers with circulating tumor cells in metastatic breast cancer","volume":"2","author":"Lohmann","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"2021110213250350400_hvab131-B24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lungcan.2018.07.005","article-title":"Prediagnosis weight loss, a stronger factor than BMI, to predict survival in patients with lung cancer","volume":"126","author":"Morel","year":"2018","journal-title":"Lung Cancer"},{"key":"2021110213250350400_hvab131-B25","doi-asserted-by":"crossref","first-page":"28010","DOI":"10.1038\/srep28010","article-title":"Characterization of different CTC subpopulations in non-small cell lung cancer","volume":"6","author":"Hanssen","year":"2016","journal-title":"Sci Rep"},{"key":"2021110213250350400_hvab131-B26","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.molonc.2015.05.009","article-title":"Frequent expression of PD-L1 on circulating breast cancer cells","volume":"9","author":"Mazel","year":"2015","journal-title":"Mol Oncol"},{"key":"2021110213250350400_hvab131-B27","doi-asserted-by":"crossref","first-page":"e0159397","DOI":"10.1371\/journal.pone.0159397","article-title":"High specificity in circulating tumor cell identification is required for accurate evaluation of programmed death-ligand 1","volume":"11","author":"Schehr","year":"2016","journal-title":"PLoS ONE"},{"key":"2021110213250350400_hvab131-B28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/annonc\/mdx636","article-title":"Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer","volume":"29","author":"Ili\u00e9","year":"2018","journal-title":"Ann Oncol"},{"key":"2021110213250350400_hvab131-B29","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3390\/cancers11060806","article-title":"PD-L1 expression with epithelial mesenchymal transition of circulating tumor cells is associated with poor survival in curatively resected non-small cell lung cancer","volume":"11","author":"Manjunath","year":"2019","journal-title":"Cancers"},{"key":"2021110213250350400_hvab131-B30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.canlet.2019.10.041","article-title":"PD-L1+ aneuploid circulating tumor endothelial cells (CTECs) exhibit resistance to the checkpoint blockade immunotherapy in advanced NSCLC patients","volume":"469","author":"Zhang","year":"2020","journal-title":"Cancer Lett"},{"key":"2021110213250350400_hvab131-B31","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.cllc.2019.03.004","article-title":"Heterogeneous expression of programmed death receptor-ligand 1 on circulating tumor cells in patients with lung cancer","volume":"20","author":"Koh","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"2021110213250350400_hvab131-B32","doi-asserted-by":"crossref","first-page":"10255","DOI":"10.1038\/s41598-017-10925-7","article-title":"PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep"},{"key":"2021110213250350400_hvab131-B33","doi-asserted-by":"crossref","first-page":"e1356145","DOI":"10.1080\/2162402X.2017.1356145","article-title":"EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer","volume":"6","author":"Dong","year":"2017","journal-title":"Oncoimmunology"},{"key":"2021110213250350400_hvab131-B34","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1158\/1078-0432.CCR-17-0802","article-title":"Sequential tracking of PD-L1 expression and RAD50 induction in circulating tumor and stromal cells of lung cancer patients undergoing radiotherapy","volume":"23","author":"Adams","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2021110213250350400_hvab131-B35","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3390\/cancers12040867","article-title":"The role of circulating tumor cells in the metastatic cascade: biology, technical challenges, and clinical relevance","volume":"12","author":"Dianat-Moghadam","year":"2020","journal-title":"Cancers"},{"key":"2021110213250350400_hvab131-B36","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1158\/1078-0432.CCR-15-1434","article-title":"Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma","volume":"22","author":"Lou","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021110213250350400_hvab131-B37","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1038\/s41598-021-82068-9","article-title":"Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients","volume":"11","author":"Ntzifa","year":"2021","journal-title":"Sci Rep"},{"key":"2021110213250350400_hvab131-B38","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nature15748","article-title":"EMT is not required for lung metastasis but contributes to chemoresistance","volume":"527","author":"Fischer","year":"2015","journal-title":"Nature"},{"key":"2021110213250350400_hvab131-B39","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3390\/cells9081836","article-title":"Epithelial cell adhesion molecule: an anchor to isolate clinically relevant circulating tumor cells","volume":"9","author":"Eslami-S","year":"2020","journal-title":"Cells"},{"key":"2021110213250350400_hvab131-B40","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3390\/cancers11060835","article-title":"Determination of PD-L1 expression in circulating tumor cells of NSCLC patients and correlation with response to PD-1\/PD-L1 inhibitors","volume":"11","author":"Janning","year":"2019","journal-title":"Cancers"},{"key":"2021110213250350400_hvab131-B41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"Ilie","year":"2016","journal-title":"Ann Oncol"},{"key":"2021110213250350400_hvab131-B42","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jtho.2020.04.026","article-title":"Programmed Death-Ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC","volume":"15","author":"Hong","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2021110213250350400_hvab131-B43","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2018.04.001","article-title":"PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab","volume":"120","author":"Guibert","year":"2018","journal-title":"Lung Cancer"},{"key":"2021110213250350400_hvab131-B44","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.annonc.2020.01.065","article-title":"Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas","volume":"31","author":"Schoenfeld","year":"2020","journal-title":"Ann Oncol"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/advance-article-pdf\/doi\/10.1093\/clinchem\/hvab131\/39590435\/hvab131.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/67\/11\/1503\/41047357\/hvab131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/67\/11\/1503\/41047357\/hvab131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T17:58:44Z","timestamp":1635875924000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/67\/11\/1503\/6342828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":44,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,1]]},"published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvab131","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,11,1]]}}}